OPT 1.27% 78.0¢ opthea limited

Ann: Opthea Phase 2b wAMD trial fully recruited ahead of schedule, page-2

  1. 507 Posts.
    lightbulb Created with Sketch. 79
    While I mentioned a few days back this impending announcement was a positive sign for Opthea there are are definitely no certainties in biotech investing and this goes for Opthea going forward. It's a very risky business. RAP, MSB and FTT have been negatively impacted to varying degrees by trial results that have not met all end points, or in the case of FTT a therapy that was effectively proved to be no better than the the placebo. My heart goes out to FTT holders some of which lost 6 figure sums on their holdings.
 
watchlist Created with Sketch. Add OPT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.